Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine
•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunization...
Gespeichert in:
Veröffentlicht in: | Veterinary immunology and immunopathology 2017-03, Vol.185, p.20-33 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 33 |
---|---|
container_issue | |
container_start_page | 20 |
container_title | Veterinary immunology and immunopathology |
container_volume | 185 |
creator | Lopera-Madrid, Jaime Osorio, Jorge E. He, Yongqun Xiang, Zuoshuang Adams, L. Garry Laughlin, Richard C. Mwangi, Waithaka Subramanya, Sandesh Neilan, John Brake, David Burrage, Thomas G. Brown, William Clay Clavijo, Alfonso Bounpheng, Mangkey A. |
description | •Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine.
A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine. |
doi_str_mv | 10.1016/j.vetimm.2017.01.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7112906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165242717300351</els_id><sourcerecordid>2000382846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYnoa_gChLNkk2I6T2Buk1ojHSINY8Nhajl0eqkmcwU6C5gv4bdx0M8AGVparbt16HEKeMFoxytrn-2qFGcex4pR1FWUVpeIe2TDZ1SVvanGfbLKsKbng3Rk5T2lPKW2UlA_JGZdcMKXUhnx_bzzMt4UJrshmS5iuIaDFHJp8MZpxNAOaUFgYhsJBxBXcT_HbyaHH_PlkrMWAptiFLyaaYgU7TzEndj6izaXpGwYoPKwQi7T0S8A5O8yYG6UCT_lH5IE3Q4LHp3dLPr56-eHiTXn17vXlxe6qtEK1cwm8B0U5dN63zDfKdK2qa2hU31vRul5KCsAtdbXvmQLaioblAAhJW1q7tt6SF0ffm6UfwVkIczSDvok4mnirJ4P670zAz_p6WnXHGFf0YPDsZBCnrwukWY-YDtcxAaYlaZ6vXEsuxf-lGRWXUvBMa0vEUWrjlFIEfzcRo_qAW-_1Ebc-4NaU6Yw7lz39c5u7ol98f68L-aYrQtTJIgQLDmPmpN2E_-7wA_9wwT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1872884225</pqid></control><display><type>article</type><title>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lopera-Madrid, Jaime ; Osorio, Jorge E. ; He, Yongqun ; Xiang, Zuoshuang ; Adams, L. Garry ; Laughlin, Richard C. ; Mwangi, Waithaka ; Subramanya, Sandesh ; Neilan, John ; Brake, David ; Burrage, Thomas G. ; Brown, William Clay ; Clavijo, Alfonso ; Bounpheng, Mangkey A.</creator><creatorcontrib>Lopera-Madrid, Jaime ; Osorio, Jorge E. ; He, Yongqun ; Xiang, Zuoshuang ; Adams, L. Garry ; Laughlin, Richard C. ; Mwangi, Waithaka ; Subramanya, Sandesh ; Neilan, John ; Brake, David ; Burrage, Thomas G. ; Brown, William Clay ; Clavijo, Alfonso ; Bounpheng, Mangkey A.</creatorcontrib><description>•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine.
A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.</description><identifier>ISSN: 0165-2427</identifier><identifier>EISSN: 1873-2534</identifier><identifier>DOI: 10.1016/j.vetimm.2017.01.004</identifier><identifier>PMID: 28241999</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>African swine fever ; African Swine Fever - immunology ; African Swine Fever - prevention & control ; African swine fever virus ; African Swine Fever Virus - genetics ; African Swine Fever Virus - immunology ; Animals ; antibodies ; Antibodies, Viral - blood ; antigens ; Antigens, Viral - genetics ; Antigens, Viral - immunology ; fluorescent antibody technique ; Genetic Vectors ; Genome, Viral ; HEK-293 ; HEK293 Cells ; Humans ; immunization ; Immunogenicity, Vaccine ; interferon-gamma ; kidneys ; macrophages ; Male ; MVA ; Recombinant protein expression ; Reverse vaccinology ; Swine ; T-lymphocytes ; T-Lymphocytes - immunology ; Vaccine development ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - immunology ; Vaccinia virus ; Vaccinia virus - genetics ; Viral Vaccines - genetics ; Viral Vaccines - immunology</subject><ispartof>Veterinary immunology and immunopathology, 2017-03, Vol.185, p.20-33</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><rights>2017 Elsevier B.V. All rights reserved. 2017 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</citedby><cites>FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165242717300351$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28241999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lopera-Madrid, Jaime</creatorcontrib><creatorcontrib>Osorio, Jorge E.</creatorcontrib><creatorcontrib>He, Yongqun</creatorcontrib><creatorcontrib>Xiang, Zuoshuang</creatorcontrib><creatorcontrib>Adams, L. Garry</creatorcontrib><creatorcontrib>Laughlin, Richard C.</creatorcontrib><creatorcontrib>Mwangi, Waithaka</creatorcontrib><creatorcontrib>Subramanya, Sandesh</creatorcontrib><creatorcontrib>Neilan, John</creatorcontrib><creatorcontrib>Brake, David</creatorcontrib><creatorcontrib>Burrage, Thomas G.</creatorcontrib><creatorcontrib>Brown, William Clay</creatorcontrib><creatorcontrib>Clavijo, Alfonso</creatorcontrib><creatorcontrib>Bounpheng, Mangkey A.</creatorcontrib><title>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</title><title>Veterinary immunology and immunopathology</title><addtitle>Vet Immunol Immunopathol</addtitle><description>•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine.
A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.</description><subject>African swine fever</subject><subject>African Swine Fever - immunology</subject><subject>African Swine Fever - prevention & control</subject><subject>African swine fever virus</subject><subject>African Swine Fever Virus - genetics</subject><subject>African Swine Fever Virus - immunology</subject><subject>Animals</subject><subject>antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>antigens</subject><subject>Antigens, Viral - genetics</subject><subject>Antigens, Viral - immunology</subject><subject>fluorescent antibody technique</subject><subject>Genetic Vectors</subject><subject>Genome, Viral</subject><subject>HEK-293</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>immunization</subject><subject>Immunogenicity, Vaccine</subject><subject>interferon-gamma</subject><subject>kidneys</subject><subject>macrophages</subject><subject>Male</subject><subject>MVA</subject><subject>Recombinant protein expression</subject><subject>Reverse vaccinology</subject><subject>Swine</subject><subject>T-lymphocytes</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccine development</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vaccinia virus</subject><subject>Vaccinia virus - genetics</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - immunology</subject><issn>0165-2427</issn><issn>1873-2534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYnoa_gChLNkk2I6T2Buk1ojHSINY8Nhajl0eqkmcwU6C5gv4bdx0M8AGVparbt16HEKeMFoxytrn-2qFGcex4pR1FWUVpeIe2TDZ1SVvanGfbLKsKbng3Rk5T2lPKW2UlA_JGZdcMKXUhnx_bzzMt4UJrshmS5iuIaDFHJp8MZpxNAOaUFgYhsJBxBXcT_HbyaHH_PlkrMWAptiFLyaaYgU7TzEndj6izaXpGwYoPKwQi7T0S8A5O8yYG6UCT_lH5IE3Q4LHp3dLPr56-eHiTXn17vXlxe6qtEK1cwm8B0U5dN63zDfKdK2qa2hU31vRul5KCsAtdbXvmQLaioblAAhJW1q7tt6SF0ffm6UfwVkIczSDvok4mnirJ4P670zAz_p6WnXHGFf0YPDsZBCnrwukWY-YDtcxAaYlaZ6vXEsuxf-lGRWXUvBMa0vEUWrjlFIEfzcRo_qAW-_1Ebc-4NaU6Yw7lz39c5u7ol98f68L-aYrQtTJIgQLDmPmpN2E_-7wA_9wwT8</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Lopera-Madrid, Jaime</creator><creator>Osorio, Jorge E.</creator><creator>He, Yongqun</creator><creator>Xiang, Zuoshuang</creator><creator>Adams, L. Garry</creator><creator>Laughlin, Richard C.</creator><creator>Mwangi, Waithaka</creator><creator>Subramanya, Sandesh</creator><creator>Neilan, John</creator><creator>Brake, David</creator><creator>Burrage, Thomas G.</creator><creator>Brown, William Clay</creator><creator>Clavijo, Alfonso</creator><creator>Bounpheng, Mangkey A.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20170301</creationdate><title>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</title><author>Lopera-Madrid, Jaime ; Osorio, Jorge E. ; He, Yongqun ; Xiang, Zuoshuang ; Adams, L. Garry ; Laughlin, Richard C. ; Mwangi, Waithaka ; Subramanya, Sandesh ; Neilan, John ; Brake, David ; Burrage, Thomas G. ; Brown, William Clay ; Clavijo, Alfonso ; Bounpheng, Mangkey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>African swine fever</topic><topic>African Swine Fever - immunology</topic><topic>African Swine Fever - prevention & control</topic><topic>African swine fever virus</topic><topic>African Swine Fever Virus - genetics</topic><topic>African Swine Fever Virus - immunology</topic><topic>Animals</topic><topic>antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>antigens</topic><topic>Antigens, Viral - genetics</topic><topic>Antigens, Viral - immunology</topic><topic>fluorescent antibody technique</topic><topic>Genetic Vectors</topic><topic>Genome, Viral</topic><topic>HEK-293</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>immunization</topic><topic>Immunogenicity, Vaccine</topic><topic>interferon-gamma</topic><topic>kidneys</topic><topic>macrophages</topic><topic>Male</topic><topic>MVA</topic><topic>Recombinant protein expression</topic><topic>Reverse vaccinology</topic><topic>Swine</topic><topic>T-lymphocytes</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccine development</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vaccinia virus</topic><topic>Vaccinia virus - genetics</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lopera-Madrid, Jaime</creatorcontrib><creatorcontrib>Osorio, Jorge E.</creatorcontrib><creatorcontrib>He, Yongqun</creatorcontrib><creatorcontrib>Xiang, Zuoshuang</creatorcontrib><creatorcontrib>Adams, L. Garry</creatorcontrib><creatorcontrib>Laughlin, Richard C.</creatorcontrib><creatorcontrib>Mwangi, Waithaka</creatorcontrib><creatorcontrib>Subramanya, Sandesh</creatorcontrib><creatorcontrib>Neilan, John</creatorcontrib><creatorcontrib>Brake, David</creatorcontrib><creatorcontrib>Burrage, Thomas G.</creatorcontrib><creatorcontrib>Brown, William Clay</creatorcontrib><creatorcontrib>Clavijo, Alfonso</creatorcontrib><creatorcontrib>Bounpheng, Mangkey A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary immunology and immunopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lopera-Madrid, Jaime</au><au>Osorio, Jorge E.</au><au>He, Yongqun</au><au>Xiang, Zuoshuang</au><au>Adams, L. Garry</au><au>Laughlin, Richard C.</au><au>Mwangi, Waithaka</au><au>Subramanya, Sandesh</au><au>Neilan, John</au><au>Brake, David</au><au>Burrage, Thomas G.</au><au>Brown, William Clay</au><au>Clavijo, Alfonso</au><au>Bounpheng, Mangkey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</atitle><jtitle>Veterinary immunology and immunopathology</jtitle><addtitle>Vet Immunol Immunopathol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>185</volume><spage>20</spage><epage>33</epage><pages>20-33</pages><issn>0165-2427</issn><eissn>1873-2534</eissn><abstract>•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine.
A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28241999</pmid><doi>10.1016/j.vetimm.2017.01.004</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-2427 |
ispartof | Veterinary immunology and immunopathology, 2017-03, Vol.185, p.20-33 |
issn | 0165-2427 1873-2534 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7112906 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | African swine fever African Swine Fever - immunology African Swine Fever - prevention & control African swine fever virus African Swine Fever Virus - genetics African Swine Fever Virus - immunology Animals antibodies Antibodies, Viral - blood antigens Antigens, Viral - genetics Antigens, Viral - immunology fluorescent antibody technique Genetic Vectors Genome, Viral HEK-293 HEK293 Cells Humans immunization Immunogenicity, Vaccine interferon-gamma kidneys macrophages Male MVA Recombinant protein expression Reverse vaccinology Swine T-lymphocytes T-Lymphocytes - immunology Vaccine development Vaccines, Synthetic - genetics Vaccines, Synthetic - immunology Vaccinia virus Vaccinia virus - genetics Viral Vaccines - genetics Viral Vaccines - immunology |
title | Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A13%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20immunogenicity%20of%20mammalian%20cell%20derived%20and%20Modified%20Vaccinia%20Ankara%20vectored%20African%20swine%20fever%20subunit%20antigens%20in%20swine&rft.jtitle=Veterinary%20immunology%20and%20immunopathology&rft.au=Lopera-Madrid,%20Jaime&rft.date=2017-03-01&rft.volume=185&rft.spage=20&rft.epage=33&rft.pages=20-33&rft.issn=0165-2427&rft.eissn=1873-2534&rft_id=info:doi/10.1016/j.vetimm.2017.01.004&rft_dat=%3Cproquest_pubme%3E2000382846%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1872884225&rft_id=info:pmid/28241999&rft_els_id=S0165242717300351&rfr_iscdi=true |